key: cord-0884184-sieijuve
authors: Hopkins, Sarah E.; Desai, Jay; Benson, Leslie
title: Acute Flaccid Myelitis: A call for vigilance and an update on management
date: 2020-09-10
journal: Pediatr Neurol
DOI: 10.1016/j.pediatrneurol.2020.09.003
sha: 76c507cf954f71a59b3723a99e6f92d66a790bf7
doc_id: 884184
cord_uid: sieijuve

Acute flaccid myelitis (AFM) is an emerging disorder defined by the acute onset of flaccid paralysis with a longitudinally extensive, gray matter predominant, lesion of the spinal cord. AFM presents as asymmetric, proximal more than distal, weakness of one or more extremities and may cause rapid respiratory decline. Early recognition and testing are essential to monitor for complications and maximize yield of testing for infectious agents, and thus contribution to surveillance. There is no human data to support specific recommendations for treatment. However, it is encouraging that monoclonal antibodies to enterovirus D68 limit the course of disease and improve outcomes in a mouse model. Patients show functional improvement over time with multimodal rehabilitation services and consideration of nerve transfer surgery, but most have lasting sequelae. We provide basic recommendations for educating front line providers, initial testing and management, and long term monitoring for complications.

An increase in acute flaccid paralysis with a longitudinal gray matter lesion of the spinal cord was noted in California in 2012 1 . Additional cases in California, Colorado and across the US followed in 2014 2 , resulting in CDC surveillance with a case of acute flaccid myelitis (AFM) defined as a patient <18 with the acute onset of flaccid paralysis in the setting of a longitudinal, gray-matter predominant, lesion of the spinal cord. There were subsequent biennial increases in cases of AFM, to a maximum of 238 US cases spread over 42 states in 2018 3 . This biennial occurrence presents unique challenges. Just as public and health care provider vigilance begin to wane, we approach another season. With focus and energy diverted to the COVID-19 pandemic, 2020 may be even more testing. We aim to review AFM basics, provide guidance on testing and reporting, and discuss the current state of research and therapeutics.

We encourage child neurologists to maintain a high level of suspicion for AFM, to review the diagnosis with local front line providers, and to have a plan for rapid evaluation and management of these patients.

Children with AFM typically present with proximal greater than distal, asymmetric paralysis of one or more extremities with or without bulbar or cranial nerve findings in the setting of a recent or current febrile illness. Weakness may be preceded by pain in the affected extremity, leading to misdiagnoses of joint conditions or trauma. Weakness may progress over hours to several days to multiple extremity weakness and respiratory decline, with. 33% of patients requiring respiratory support 4 . Findings on neurologic examination include low muscle tone with decreased or absent deep tendon reflexes and typically intact sensation. Weakness is flaccid in the primarily involved extremity, but in cases with severe cord edema there may be secondary upper motor neuron signs, particularly in the lower J o u r n a l P r e -p r o o f extremities. There may be bulbar and/or cranial nerve findings. Given the sudden loss of muscle tone and decreased movement in addition to the spinal cord lesion, patients are also at risk for constipation and urinary retention.

Notably, AFM is a diagnosis easy to miss early in the presentation as subtle weakness associated with pain may be thought to be due to trauma, or to viral illness. Close examination of all patients for proximal muscle weakness (high five, shoulder shrug, stoop and recover, stand from floor without using hands) and hyporeflexia is essential to avoid missing an early presentation of AFM.

Earlier viral testing increases yield, so specimens should be obtained as quickly as possible. Viral testing is minimal risk, and samples, respiratory in particular, should be obtained as soon as the diagnosis of AFM is suspected, without waiting for magnetic resonance imaging (MRI) confirmation. Table 1 Unfortunately, there remain no clear recommendations for optimal medical treatment of AFM. IVIG is often used to boost humoral immunity, and showed efficacy when given early in a mouse model 6 .

Steroids and plasma exchange have been used, and theoretically may have benefit in cases with significant spinal cord edema and long tract signs; however, timing and potential risk of exacerbating underlying infection should be carefully considered on a case by case basis. Several centers around the country tried fluoxetine in 2015-16 but a retrospective analysis of data revealed no benefit.

Recent data from colleagues at Vanderbilt demonstrates that, in a mouse model, anti-enterovirus D68

antibodies may limit the course of AFM, and are associated with marked recovery in the mouse model 7 .

Whether these antibodies will be developed as a safe and effective therapy for humans with AFM remains to be seen, but the data is encouraging.

Early involvement of pediatric rehabilitation is key to maximizing functional outcomes. Bracing must balance safety and use of the muscles. In addition, nerve and muscle transfer surgeries may be considered to maximize function in select patients 8 In addition to surveillance, the NIH/NIAID AFM Natural History Study begins this year. Clinicians interested in enrolling patients may find additional information here: https://www.cdc.gov/acuteflaccid-myelitis/parents/get-involved-afm-research.html.

AFM is associated with significant morbidity. Early consideration of the diagnosis and testing is key to identifying the etiology, keeping patients safe, and contributing key data to surveillance. We hope that recent research will lead to additional treatments for AFM; in which case early diagnosis will be key to effective treatment. We ask child neurologists to reach out to front line providers in their region to remind them about AFM, and urge institutions to have clear protocols in place for testing and management.

J o u r n a l P r e -p r o o f

Acute flaccid myelitis of unknown etiology in California

Acute flaccid myelitis: A clinical review of US cases 2012-2015

CDC. AFM Cases and Outbreaks

Acute flaccid myelitis in the United States

Outcomes of Colorado children with acute flaccid myelitis at 1 year

Evaluating Treatment Efficacy in a Mouse Model of Enterovirus D68-Associated Paralytic Myelitis

Human antibodies neutralize enterovirus D68 and protect against infection and paralytic disease

Early results of nerve transfers for restoring function in severe cases of acute flaccid myelitis

Acute flaccid myelitis: Rehabilitation challenges and outcomes in a pediatric cohort